Although there are various tyrosine kinase inhibitors (TKIs; e.g., sorafenib, lenvatinib, regorafenib, and cabozantinib) and monoclonal antibodies against PD-L1 (atezolizumab plus bevacizumab) currently available for the treatment of advanced HCC, the response rate is low, and the acquired resistance has become an increasing problem [34]. This evidence concerns the gene CD274 and hepatocellular carcinoma.